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The increasing global prevalence of diabetes has been accompanied by a rise
in diabetes-related conditions. This includes diabetic cardiomyopathy (DbCM), a
progressive form of heart disease that occurs with both insulin-dependent (type-1)
and insulin-independent (type-2) diabetes and arises in the absence of hypertension
or coronary artery disease. Over time, DbCM can develop into overt heart failure. Like
other forms of cardiomyopathy, DbCM is accompanied by alterations in metabolism
which could lead to further progression of the pathology, with metabolic derangement
postulated to precede functional changes in the diabetic heart. Moreover in the case of
type-2 diabetes, underlying insulin resistance is likely to prevent the canonical substrate
switch of the failing heart away from fatty acid oxidation toward increased use of
glycolysis. Analytical chemistry techniques, collectively known as metabolomics, are
useful tools for investigating the condition. In this article, we provide a comprehensive
review of those studies that have employed metabolomic techniques, namely
chromatography, mass spectrometry and nuclear magnetic resonance spectroscopy,
to profile metabolic remodeling in the diabetic heart of human patients and animal
models. These studies collectively demonstrate that glycolysis and glucose oxidation
are suppressed in the diabetic myocardium and highlight a complex picture regarding
lipid metabolism. The diabetic heart typically shows an increased reliance on fatty acid
oxidation, yet triacylglycerols and other lipids accumulate in the diabetic myocardium
indicating probable lipotoxicity. The application of lipidomic techniques to the diabetic
heart has identified specific lipid species that become enriched and which may in
turn act as plasma-borne biomarkers for the condition. Metabolomics is proving to
be a powerful approach, allowing a much richer analysis of the metabolic alterations
that occur in the diabetic heart. Careful physiological interpretation of metabolomic
results will now be key in order to establish which aspects of the metabolic
derangement are causal to the progression of DbCM and might form the basis for novel
therapeutic intervention.
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INTRODUCTION
Expansion of the global population and an increase in age-
standardized prevalence (Palermo et al., 2014) have together
contributed to a rapid escalation in the worldwide incidence of
diabetes mellitus (NCD Risk Factor Collaboration (NCD-RisC),
2016). Whilst diabetes is associated with a wide variety of clinical
complications, cardiovascular diseases account for approximately
65% of diabetes-related mortality (Pappachan et al., 2013). CAD
and hypertension are both highly prevalent in the diabetic
population, however the risk of heart failure is elevated in patients
with diabetes even when CAD and hypertension are taken into
account (Hölscher et al., 2016). This increased susceptibility to
failure is attributed to a collection of metabolic, functional, and
morphological derangements to the myocardium, collectively
termed DbCM. Clinically, DbCM is defined as the presence of
myocardial dysfunction in a diabetic patient in the absence of
classical cardiovascular risk factors, such as CAD, hypertension,
or valve disease (Jia et al., 2018). The very existence of DbCM
has been considered controversial, although it is now generally
accepted as a distinct form of heart disease demonstrable in
both animal models and human patient cohorts (Ernande and
Derumeaux, 2012). Prolonged hyperglycemia, accompanied by
systemic insulin resistance in the case of type-2 diabetes (T2DM),
is considered central to the etiology of DbCM (Bell, 2003). It
is a progressive condition that initially presents as subclinical
ventricular hypertrophy and fibrosis, but can develop into overt
heart failure with systolic dysfunction (Jia et al., 2018).
Heart failure is classically defined as an inability of the
heart to deliver sufficient blood to the tissues of the body
to meet metabolic demands (Braunwald, 1978). It can arise
due to a number of underlying causes and is a multifactorial
condition, but alterations in cardiac metabolism and energetics
are now considered to be important features of the underlying
pathology (Neubauer, 2007). The healthy heart is metabolically
flexible, predominantly employing FA oxidation to meet ATP
requirements, but with a further significant contribution from
glucose oxidation depending upon circumstances, and smaller
contributions from the oxidation of lactate, ketone bodies, and
BCAAs (Bing et al., 1954). It is commonly reported that the
failing heart undergoes a substrate ‘switch’ with the proportion
of ATP derived from glycolysis exceeding that from FA oxidation
(Neubauer, 2007). This may represent an overall impairment
Abbreviations: ADP, adenosine diphosphate; ATP, adenosine triphosphate;
BCAA, branched-chain amino acid; CAD, coronary artery disease; DAG,
diacylglycerol; DbCM, diabetic cardiomyopathy; ESI, electronspray ionization;
FA, fatty acid; FFA, free fatty acid; FID, flame ionization detector; GC, gas
chromatography; HFD, high fat diet; HFSD, high fat, high sucrose diet;
HPLC, high-performance liquid chromatography; HPTLC, high-performance
thin-layer chromatography; LC, liquid chromatography; MRI, magnetic resonance
imaging; MRS, magnetic resonance spectroscopy; MS, mass spectrometry; MSI,
mass spectrometry imaging; NMR, nuclear magnetic resonance; OXPHOS,
oxidative phosphorylation; PC, phosphatidylcholine; PCr, phosphocreatine; PDH,
pyruvate dehydrogenase; PE, phosphatidylethanolamine; PET, positron emission
tomography; PI, phosphatidylinositol; PS, phosphatidylserine; QToF, quadrupole,
time of flight; SM, sphingomyelin; STZ, streptozotocin; T1DM, type-1 diabetes
mellitus; T2DM, type-2 diabetes mellitus; TAC, thoracic aortic constriction; TAG,
triacylglycerol; TCA, tricarboxylic acid; TCD, thermal conductivity detector; TLC,
thin-layer chromatography; ZDF, Zucker diabetic fatty rat.
in oxidative capacity, since several studies have reported an
impairment in glucose oxidation in the failing heart (Zhabyeyev
et al., 2013; Seymour et al., 2015; Diakos et al., 2016; Kaimoto
et al., 2017), with a decreased mitochondrial OXPHOS capacity
being associated with a diminished energetic reserve in the
myocardium (Stanley et al., 2005). Furthermore, the failing heart
becomes insulin resistant (Swan et al., 1994), eventually limiting
the capacity for glucose catabolism to meet energetic demands,
with ketone body oxidation possibly increasing in later stages of
the condition (Aubert et al., 2016; Bedi et al., 2016).
Diabetic cardiomyopathy, however, is considered to differ
from other causes of heart failure. Metabolic disturbances
precede the first signs of mechanical failure in the diabetic
myocardium and are considered likely to be causative (Jia
et al., 2018). Moreover, in contrast with animal models of, e.g.,
pressure-overload or ischemic heart failure (Rosca and Hoppel,
2010), mitochondrial content has been reported to be increased in
the hearts of diabetic rodents, whilst proportionally, FA oxidation
increases and glucose oxidation is depressed (Bugger and Abel,
2010). Whilst this metabolic profile would appear to differ from
that of the failing non-diabetic heart, what unifies the two
pathologies is a loss in metabolic flexibility, potentially impairing
the capacity of the heart to utilize the most appropriate substrate
depending on circumstance. Whilst metabolic and energetic
derangements are considered to be core to the etiology of DbCM
and the progression to failure, the time-course of metabolic
alterations with respect to functional and morphological changes,
and in conjunction with eventual failure of the myocardium,
remains unclear.
The growing field of metabolomics employs a collection
of analytical techniques which have the potential to elucidate
this progression of metabolic disturbances in the diabetic heart
and may additionally highlight novel plasma-borne biomarkers.
In this review, we first give a brief overview of some of the
most commonly used metabolomic techniques and models,
before considering in detail those studies that have applied
these techniques to investigate metabolic changes in the diabetic
heart. In particular, we draw attention to the growing field of
lipidomics and how alterations to plasma lipid species could serve
as putative biomarkers for DbCM. Finally, we highlight how
existing and emerging metabolomic technologies could be used
to address some of the remaining questions concerning cardiac
metabolism in diabetes.
AN OVERVIEW OF METABOLOMICS AND
METABOLOMIC METHODS
The comprehensive study of all metabolites in a biological
system is referred to as metabolomics (Dunn et al., 2011). In
comparison with proteins and nucleic acids, metabolites have
a relatively low molecular weight (<1500 Da), exist across
a wide range of concentrations and have extremely diverse
chemical properties (Dunn et al., 2011). This can make the
detection, identification and (semi-) quantification of metabolites
a technical challenge. Nevertheless, the application of analytical
chemistry techniques such as NMR spectroscopy, MS and
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chromatography, coupled to the production and expansion of
data libraries such as the Human Metabolome Database (Wishart
et al., 2007), has led to the development of both unbiased
and targeted assays for high-throughput metabolic profiling and
analysis (O’Brien et al., 2015).
Nuclear Magnetic Resonance
Spectroscopy
Nuclear magnetic resonance utilizes a quantum property of
certain atomic nuclei, known as spin, to visualize the structure
of a chemical species. When exposed to a magnetic field, these
nuclei assume different energy levels which can be detected using
radio waves (Griffin et al., 2011). The chemical environment of
a particular nucleus affects the resonant frequency at which that
nucleus will be detected, a phenomenon known as the chemical
shift, and as such structural information can be determined
from NMR spectra (Griffin et al., 2011). Atoms such as 1H,
13C, and 31P have nuclei with a quantum spin number of 1/2,
and therefore have two energy levels which can be detected by
NMR spectroscopy. Helpfully, these nuclei are also ubiquitous
across metabolic species in biological systems, making NMR
a highly valuable tool in metabolomic studies (Griffin et al.,
2011). 1H-NMR is particularly useful in metabolomic analysis
owing to its greater relative sensitivity, which arises from the
higher gyromagnetic ratio of 1H in comparison with other nuclei
(Derome, 1987).
Nuclear magnetic resonance is non-destructive, allowing
multiple analyses to be carried out on a single sample (Dunn et al.,
2011). This has also permitted application of the technique to
living systems, allowing the in vivo measurement of metabolites
in MRS studies (see for example, Szczepaniak et al., 2003;
Reingold et al., 2005; Perseghin et al., 2007; Bilet et al., 2011).
Although only a small number of metabolites can be measured
in vivo, these include ATP and PCr using 31P-MRS, allowing
tissue energetics to be investigated. Moreover, biopsy samples are
not required and the technique does not use ionizing radiation,
thus MRS has increased the potential for recruiting patient
cohorts of a meaningful size for studies of metabolism (e.g.,
Neubauer et al., 1997).
The structural information that can be determined from
NMR spectra can allow the identification of metabolites in an
unbiased manner (Dunn et al., 2011). A major disadvantage
of NMR, however, is its low sensitivity especially in relation
to other metabolomic techniques, and it is therefore limited
to the detection of metabolites present at high concentrations
in vivo (Dunn et al., 2011). One method that has increased
the sensitivity of such measurements is hyperpolarized NMR
(Schroeder et al., 2008, 2009, 2011). Hyperpolarization improves
sensitivity by enhancing the polarization of the nucleus of
interest, thereby increasing the signal that can be detected by
an NMR/MRS scanner (Golman et al., 2008). Through the
introduction of a specific metabolite labeled with hyperpolarized
13C, for example, the enzymatic conversion through metabolic
pathways, such as the TCA cycle, can be observed in real time
with a resolution as low as 1 s (Schroeder et al., 2009). However,
a major limitation of hyperpolarized NMR is that only a small
number of metabolites (e.g., [1-13C]-pyruvate) can be usefully
studied, and this depends on both physicochemical properties
(e.g., relaxation, polarization) and biological properties (e.g.,
safety, pharmacokinetics) of the molecule (Miloushev et al.,
2016). Hyperpolarized NMR spectroscopy is therefore highly
useful when measuring the in vivo kinetics of a particular enzyme
of interest, such as PDH (Schroeder et al., 2008; Atherton
et al., 2011), but is not suitable for identifying more global
metabolic changes.
Mass Spectrometry
Mass spectrometry initially requires the ionization of analytes
in a sample of interest, before the separation and detection of
individual ions on the basis of their mass-to-charge (m/z) ratio
(Dunn et al., 2011). Determination of the specific analyte, or
metabolite in the case of metabolomics, is achieved through
comparison of spectra with pure chemical standards or publicly-
available data repositories. MS is a highly sensitive technique, and
is able to detect and identify significantly more metabolites than
is possible with NMR (Griffin et al., 2011). It can, however, be
difficult to distinguish between different isomers of molecules,
or between non-isomeric species of the same molecular weight
(Griffin et al., 2011).
Mass spectrometry is often coupled to chromatographic
separation, usually either GC or LC, which can greatly expand
the number of metabolites that can be detected (Dunn et al.,
2011). Samples can, however, also be directly introduced to mass
spectrometers, often in an automated manner, increasing the
throughput of the analysis (Dunn et al., 2011). This method
of direct-infusion mass spectrometry (DIMS) requires high
resolution instrumentation to ensure adequate discrimination
of metabolite species (Griffin et al., 2011). DIMS is often used
in lipid analysis, where it is sometimes referred to as shotgun
lipidomics (Griffin et al., 2011), although it can also be used to
profile aqueous metabolites.
Chromatography
Chromatography refers to the separation of different molecular
species in a mixture, such as a biofluid or tissue extract. A column
is utilized, through which different analytes pass at different rates
depending on their chemical properties and that of the column
used. The time taken for a particular metabolite to elute from the
chromatographic column is referred to as the retention time, and
this can be used for molecular identification.
Two chromatographic techniques are commonly employed
in metabolomic studies: GC and LC, which differ in the phase
in which metabolites are separated. GC uses a long column to
separate metabolites in the gaseous phase. This can be beneficial
when coupled to MS, since metabolites are already volatile when
entering the mass spectrometer (Griffin et al., 2011). LC separates
metabolites dissolved in a liquid by partitioning them between
the liquid and solid phase. However, because metabolites are in
the liquid phase they cannot be directly introduced to a mass
spectrometer following elution from the column. To overcome
this, ESI is often used, whereby the metabolite-containing liquid
is aerosolized, forming charged particles that can then enter
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the mass spectrometer (Griffin et al., 2011). GC is considered
more robust than LC in terms of reproducibility, since retention
time shift during any given analytical run tends to be more
modest (Griffin et al., 2011). However, as many metabolites are
not volatile, samples often have to be derivatized before GC
analysis, which is often not the case in LC and more metabolites
can therefore be analyzed by LC–MS compared with GC–MS
(Griffin et al., 2011).
Although chromatography is usually coupled to MS,
other techniques for identifying metabolites following
chromatographic separation can also be employed. Examples
of alternative detectors include FIDs and TCDs, which can be
used to identify analytes as they are eluted from GC columns
(Zuo et al., 2013).
Targeted Analysis Versus Open-Profiling
Metabolomic studies are often subdivided into open-profiling
and targeted analyses. Open-profiling involves detecting and
measuring all (or at least as many as possible) of the metabolites
in a sample, and is therefore sometimes referred to as unbiased
metabolomics (Dunn et al., 2011). Such studies are typically
hypothesis-generating and are useful, for instance, in the
discovery of biomarkers in particular disease states, as well
as for the discovery of novel metabolites associated with
a particular process (Griffin et al., 2011). Targeted analysis,
however, involves the measurement of a limited number of
pre-defined metabolites, and is therefore typically employed in
hypothesis-testing experiments (Griffin et al., 2011). Targeted
analysis is often more sensitive than open-profiling, and can
be used to provide absolute quantification of metabolites of
interest (Dunn et al., 2011). In the particular case of DbCM,
targeted analysis has generally been used to investigate changes
in energetic status or substrate preference in the diabetic
heart (see sections “High-Energy Phosphate Metabolism in
the Diabetic Heart” and “Substrate Preference of the Diabetic
Heart: Glucose and Fatty Acid Metabolism”), whilst more open-
profiling lipidomic techniques are being employed to investigate
changes to individual lipid species that may serve as putative
biomarkers for the condition (see section “Lipidomics: A Tool for
Biomarker Discovery in DbCM”).
ANIMAL MODELS OF DIABETES,
OBESITY, AND THE METABOLIC
SYNDROME
A number of animal models of diabetes, obesity and the
metabolic syndrome [a pre-diabetic state characterized by
obesity, hypertension, hyperglycemia, hyperinsulinemia, and
dyslipidemia (Dandona et al., 2005)] have been developed and
characterized, and these have been comprehensively reviewed in
a number of previous publications (Rees and Alcolado, 2005;
Bugger and Abel, 2009; Lutz and Woods, 2012; Wang et al., 2014;
Wong et al., 2016). Many of these models have been vital in the
research of DbCM, including in metabolomic studies, and some
of the key models will be briefly introduced here.
Rodents are the most commonly used animal models of
diabetes, and, broadly speaking, they can be divided into genetic
and inducible models. The most common genetic models are
summarized below (Table 1). A number of these models arose
from mutations in the genes encoding either the satiety hormone
leptin [e.g., the ob/ob mouse (Friedman et al., 1991; Zhang et al.,
1994)] or that of its receptor [e.g., the db/db mouse (Hummel
et al., 1966; Chen et al., 1996)]. The Zucker fatty rat, which is
obese and shows features of the metabolic syndrome (Zucker and
Zucker, 1961; Zucker and Antoniades, 1972), also resulted from
a mutation in the leptin receptor gene, whilst selective breeding
of Zucker fatty rats gave rise to the more severe phenotype of the
ZDF rat (Shiota and Printz, 2012; Lehnen et al., 2013). In all cases,
these loss-of-function mutations result in hyperphagia, with
the rodents experiencing chronic over-nutrition which rapidly
develops into obesity and hyperinsulinemia, and can eventually
lead to β-cell dysfunction and a severe diabetic phenotype similar
to the clinical manifestation of T2DM (Wang et al., 2014).
In contrast, the Akita mouse represents a genetic model of
T1DM, brought about via a missense mutation in the gene
encoding insulin (Yoshioka et al., 1997; Wang et al., 1999).
Another common genetic model of T1DM is the non-obese
diabetic (NOD) mouse, a polygenic model which develops the
disease through autoimmune destruction of the pancreatic β-cells
(Wicker et al., 1987; Serreze and Leiter, 1994).
Whilst the models listed in Table 1 arose due to spontaneous
mutations that occurred in laboratory rodent colonies, modern
genetic engineering techniques have enabled generation of mice
with specific desired mutations. Examples of such animals that
have been used in metabolomic studies of DbCM include the
βV59M mouse, a model of human neonatal diabetes that can
be rapidly induced and reversed, which has a mutation in the
pancreatic β-cell ATP-sensitive K+ channel (Girard et al., 2009;
Rohm et al., 2018), and the glycerol-3-phosphate acyltransferase 1
knockout (Gpat1−/−) mouse which exhibits a diabetic phenotype
owing to alterations to cardiac glycerol-phosphate metabolism
(Lewin et al., 2008).
As an alternative to genetic models, diabetes can be induced
through administration of a diabetogenic toxin or diet. The
antibiotic, STZ, or alloxan (a toxic glucose analog) are commonly
used to induce diabetes in rats or mice through the destruction
of pancreatic β-cells (Shaw Dunn et al., 1943; Rossini et al.,
1977). Such compounds can be administered intravenously (i.v.)
or intraperitoneally (i.p.) (Rossini et al., 1977), and result in the
development of a severe T1DM phenotype (Wu and Yan, 2015).
High fat diets are often used to induce obesity and
the metabolic syndrome in rodent models (Buettner et al.,
2007). Since insulin resistance and/or glucose intolerance are
characteristics of metabolic syndrome, HFD-fed rodent models
are commonly used for investigations into T2DM (Buettner
et al., 2007), however overt T2DM does not always develop
with HFD feeding. In order to expedite the development of
T2DM, high-fat, high-sugar diets (with high fructose or sucrose
content) can be used, which are especially diabetogenic on certain
rodent backgrounds such as the C57BL/6J mouse (Surwit et al.,
1988). Alternatively, high-fat feeding has been combined with
a low-dose injection of STZ to generate a reproducible T2DM
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TABLE 1 | Common genetic rodent models of diabetes, obesity, and the metabolic syndrome.
Model Species Gene mutation Condition Modeled
Akita Mouse Insulin missense T1DM (Yoshioka et al., 1997; Wang et al., 1999)
NOD Mouse Polygenic T1DM (Wicker et al., 1987; Serreze and Leiter, 1994)
db/db Mouse Leptin receptor, splice variant T2DM (Hummel et al., 1966; Chen et al., 1996)
ob/ob Mouse Leptin, nonsense Obesity, features of T2DM/MetS (Friedman et al., 1991; Zhang et al., 1994)
Zucker Fatty Rat Leptin receptor, missense Obesity, features of MetS (Zucker and Zucker, 1961; Zucker and Antoniades, 1972)
ZDF Rat Leptin receptor, missense T2DM (Shiota and Printz, 2012; Lehnen et al., 2013)
T1DM, type-1 diabetes; T2DM, type-2 diabetes; MetS, metabolic syndrome; NOD, non-obese diabetic; ZDF, Zucker diabetic fatty.
phenotype (Srinivasan et al., 2005). Such HFD models have
been used to investigate alterations to cardiac metabolism in
the diabetic heart by both metabolomic (e.g., Mansor et al.,
2013; Abdurrachim et al., 2014; Le Page et al., 2015) and non-
metabolomic methods, such as radio-labeled substrate utilization
or measurements of mitochondrial respiratory capacity (e.g., Reid
et al., 1970; Cole et al., 2011; Boardman et al., 2017).
HIGH-ENERGY PHOSPHATE
METABOLISM IN THE DIABETIC HEART
It has long been postulated that the failing heart is energy-
starved, with the hypothesis first put forward in the 1930s
(Herrmann and Decherd, 1939). The advent of MRS technology,
and specifically 31P-MRS, has allowed measurements to be made
of the myocardial PCr to ATP ratio (PCr/ATP) in vivo as an
index of cardiac energy reserve. The creatine kinase system
acts to temporally and spatially buffer ATP in the myocardium,
transferring phosphate groups from ATP to creatine at the
mitochondria and from PCr to ADP at the myofibrils (Wallimann
et al., 2011). This acts to maintain ADP levels in the mitochondria
to support OXPHOS and ATP levels at the myofibrils to support
contraction, particularly under conditions of increased ATP
demand (Neubauer, 2007). A fall in myocardial PCr/ATP can
therefore indicate that ATP synthesis is not keeping pace with
cellular energy demand.
PCr/ATP is decreased in failing human hearts, appearing to
confirm the energy-starvation hypothesis, and this index was
additionally found to predict mortality in patients with dilated
cardiomyopathy (DCM) (Neubauer et al., 1997). 31P-MRS has
also been employed to measure PCr/ATP in diabetic patients,
as well as animal models, however evidence that the diabetic
myocardium is energy-starved is a little less clear (Table 2).
Whilst a number of studies in both rodents and humans have
demonstrated a lower PCr/ATP in the diabetic myocardium
(Diamant et al., 2003; Scheuermann-Freestone et al., 2003; Liang
et al., 2015; Levelt et al., 2016a,b; Abdurrachim et al., 2017), others
found no difference in myocardial energy reserve compared with
controls (Spindler et al., 1999; Bollano et al., 2007; Rijzewijk et al.,
2009; Abdurrachim et al., 2014).
These apparent discrepancies may be explained by the
model or population studied. All human studies considered in
Table 2 were carried out in T2DM cohorts, and here there is a
general consensus that PCr/ATP is depressed in the myocardium
(Diamant et al., 2003; Scheuermann-Freestone et al., 2003; Levelt
et al., 2016a,b). The one human study that found no difference
in PCr/ATP used a patient population that were transferred to
glimepiride monotherapy 8-weeks prior to the measurements
taking place (Rijzewijk et al., 2009). Glimepiride is a sulfonylurea-
class anti-diabetic therapy that increases insulin secretion from
pancreatic β-cells through blockade of the ATP-dependent
potassium channels (Davis, 2004). Although glimepiride is
believed to be pancreas-specific, it is possible that it may
TABLE 2 | Results from 31P-MRS studies in diabetic rodents and patients.
Species Measurement Model/population PCr/ATP compared with
controls
References
Mouse In vivo HFD – Abdurrachim et al., 2014
Mouse In vivo db/db ↓ Abdurrachim et al., 2017
Mouse In vivo db/db + TAC – Abdurrachim et al., 2017
Rat In vivo STZ – Bollano et al., 2007
Rat Ex vivo STZ ↓ Liang et al., 2015
Rat Ex vivo STZ -∗ Spindler et al., 1999
Human In vivo Newly diagnosed T2DM, well-controlled ↓ Diamant et al., 2003
Human In vivo T2DM on oral antidiabetic therapy ↓ Levelt et al., 2016b
Human In vivo Normotensive T2DM subjects ↓ Levelt et al., 2016a
Human In vivo Male T2DM – Rijzewijk et al., 2009
Human In vivo T2DM, 18–75 years old, no evidence of cardiac ischemia ↓ Scheuermann-Freestone et al., 2003
–No difference in PCr/ATP between diabetic and control groups. ↓ PCr/ATP is lower in diabetic subjects compared with controls. ∗ Inferred from measured levels of PCr
and ATP. HFD, high fat diet; TAC, thoracic aortic constriction; STZ, streptozotocin; T2DM, type-2 diabetes.
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beneficially affect the cardiovascular system (Davis, 2004), either
directly or indirectly via improvements in insulin secretion.
Whilst the other human studies considered in Table 2 include
patients taking sulfonylureas, they also included patients on other
forms of oral anti-diabetic agents, such as metformin, and thus
the anomalous results may reflect a specific effect of glimepiride.
Likewise, the different rodent models investigated reflect
slightly different diabetic states. The finding of lower PCr/ATP
in the db/db mouse (Abdurrachim et al., 2017) supports the
human data suggesting myocardial energy depletion in T2DM.
However, when exposed to pressure overload via TAC the cardiac
energetics of db/db mice were normalized (Abdurrachim et al.,
2017). It was proposed that this might be a result of restoration of
cardiac metabolic substrate balance, whereby pressure-overload
leads to increased glucose uptake and utilization thereby reducing
the reliance on FA oxidation in the diabetic heart (Abdurrachim
et al., 2017). This suggests the metabolic etiology of DbCM
contrasts with that of pressure overload-induced heart failure.
Despite also being a model of insulin resistance, the discrepancy
between the unaltered PCr/ATP in HFD-fed mice (Abdurrachim
et al., 2014) compared with overtly-diabetic db/db mice may
reflect differences in the degree of the pathology induced. Indeed,
although fasting plasma glucose levels were elevated in mice with
HFD feeding, plasma insulin levels were not significantly raised
(Abdurrachim et al., 2014), suggesting this model may reflect a
pre-diabetic or glucose intolerant state, rather than overt T2DM.
The STZ rat differs from other models, in that it represents
a form of T1DM. In the STZ rat, different results have been
reported concerning PCr/ATP when measured across three
studies, with one study showing worsened energetic reserve
(Liang et al., 2015) and two suggesting no difference (Spindler
et al., 1999; Bollano et al., 2007). These discrepancies may be
explained by the different strains of rat used [Wistar (Spindler
et al., 1999) vs. Sprague-Dawley (Bollano et al., 2007; Liang et al.,
2015)], dose of STZ [65 mg kg−1 (Spindler et al., 1999; Bollano
et al., 2007) vs. 70 mg kg−1 (Liang et al., 2015)], route of STZ
injection [i.p. (Liang et al., 2015) vs. i.v. (Spindler et al., 1999;
Bollano et al., 2007)], study length [4 weeks (Spindler et al., 1999)
vs. 6 weeks (Spindler et al., 1999; Liang et al., 2015) vs. 12 weeks
(Bollano et al., 2007)] or the age of the rats when diabetes was
induced [5–6 weeks (Spindler et al., 1999) vs. 8 weeks (Liang et al.,
2015), age not stated in Bollano et al. (2007)]. Such differences in
study design are known to confound interpretation of results in
studies utilizing STZ-induced diabetes (Deeds et al., 2011).
Although PCr/ATP is considered to be a good marker for
cellular energy reserve, there are many factors which could also
explain some of the different results reported in Table 2. For
example myocardial PCr/ATP was found to become depleted
in association with elevated plasma FA levels in healthy young
men, either as a result of fasting and exhaustive exercise (Bilet
et al., 2011) or a high-fat low-carbohydrate diet (Holloway
et al., 2011). Meanwhile, weight-loss was found to improve
myocardial PCr/ATP in obese patients, suggesting whole-body
energetic status can impact myocardial PCr/ATP (Rider et al.,
2013). This is supported by a study in healthy men, which
found that PCr/ATP decreased with increased body mass index
(Perseghin et al., 2007). A further study in a male T2DM cohort,
however, found that two anti-glycemic agents, metformin and
pioglitazone, did not affect cardiac high-energy phosphate levels
(van der Meer et al., 2009).
Current evidence therefore supports the notion of energy
depletion in the T2DM heart, and this may depend upon
the severity of the condition. Whether myocardial energy
depletion is a causal factor in the progressive development of
DbCM, or simply a consequence of the metabolic derailment
remains unknown.
SUBSTRATE PREFERENCE OF THE
DIABETIC HEART: GLUCOSE AND FATTY
ACID METABOLISM
A classic metabolic signature of heart failure, occurring
for example during the development of pressure overload
hypertrophy, is a relative switch in substrate preference
away from FA oxidation and toward glucose metabolism,
particularly glycolysis (Neubauer, 2007). In the diabetic heart,
evidence suggests that remodeling of substrate preference
does occur, albeit in the opposite direction to that following
pressure overload, however results from metabolomic studies
are somewhat inconsistent (Table 3). The most common and
consistent finding is that glucose metabolism, encompassing
anaerobic glycolysis and glucose oxidation, is suppressed in the
diabetic myocardium. This is in accordance with the pathology of
diabetes; insulin resistance in T2DM and lack of insulin in T1DM
result in impaired glucose uptake, whilst increased circulating
FFA concentrations (in both T1DM and T2DM) suppress glucose
oxidation through the action of the Randle cycle. This occurs
through inhibition of glycolysis and pyruvate oxidation mediated
by increased acetyl-CoA derived from β-oxidation of FFAs
(Randle et al., 1963).
Correspondingly, the capacity for pyruvate oxidation was
found to be depressed in several rodent models of diabetes.
A number of studies have employed hyperpolarized-13C MRS to
measure flux through PDH, the key enzyme linking glycolysis
to the mitochondrial citric acid cycle (Schroeder et al., 2008; Le
Page et al., 2015; Rohm et al., 2018). Flux through PDH was
found to be depressed across multiple rodent models including
the STZ rat model of T1DM, the low dose STZ + HFD-fed rat
model of T2DM (Mansor et al., 2013) and βV59M mice (Rohm
et al., 2018). One study in the STZ rat also reported that the
degree of impairment of PDH flux correlated with severity of the
diabetic phenotype (as determined by the extent of blood glucose
elevation) (Schroeder et al., 2008), which implicates restricted
pyruvate oxidation in the etiology of DbCM, although whether
this is causal has yet to be determined.
There is, however, conflicting evidence from metabolomic
studies regarding FA oxidation in the diabetic myocardium,
with studies reporting both increased and decreased capacities.
Three such studies utilized retrograde perfusion of ex vivo hearts
and included 13C-labeled FA in the perfusate to determine FA
oxidation by NMR through quantification of the incorporation
of the 13C-label into the TCA cycle metabolite pool (Chatham
and Forder, 1997; Chatham et al., 1999; Wang et al., 2005).
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Glycolysis Glucose oxidation Pyruvate oxidation Fatty acid oxidation
↓ NMR STZ rat Chatham and Forder, 1993
↓ ↓ NMR STZ rat Chatham and Forder, 1997
↓ NMR STZ rat Chatham et al., 1999
↓ ↓ NMR ZDF rat Chatham and Seymour, 2002
↓ ↑ NMR ZDF rat Wang et al., 2005
↓
13C MRS∗ STZ rat Schroeder et al., 2008
↓
13C MRS∗ STZ rat + HFD Le Page et al., 2015
↓
13C MRS∗ βV59M mice Rohm et al., 2018
Note that evidence from non-metabolomic studies more conclusively supports an increase in FA oxidation. ↓ decreased pathway flux in diabetes, ↑ increased pathway
flux in diabetes. ∗ Indicates the use of hyperpolarized NMR spectroscopy. NMR, nuclear magnetic resonance; 13C MRS, carbon-13 magnetic resonance spectroscopy;
STZ, streptozotocin; ZDF, Zucker diabetic fatty; HFD, high fat diet.
The apparent discrepancies in findings may be a result of
the model used and/or the pathology studied. FA oxidation
was found to be decreased in the hearts of T1DM STZ rats
(Chatham and Forder, 1997; Chatham et al., 1999), whilst FA
oxidation was elevated in comparison with controls in the
T2DM ZDF rat (Wang et al., 2005). Differences in metabolic
features of the development of DbCM in T1DM compared with
T2DM may underlie these apparent discrepancies, and these
have been comprehensively reviewed elsewhere (Hölscher et al.,
2016). Further differences between these two models may reflect
the progressive nature of DbCM, with lower FA oxidation in
the STZ rat perhaps reflecting a more severe form of DbCM
(Chatham and Forder, 1997; Chatham et al., 1999) characterized
by impairment of total oxidative capacity and loss of cardiac
mitochondrial content, whilst increased FA oxidation in the ZDF
rat (Wang et al., 2005) may reflect an earlier, adaptive stage of
DbCM development. Moreover, in all these studies FA oxidation
was investigated in hearts perfused ex vivo; a setting which may
not fully capture the complexity of diabetic conditions in vivo
(Larsen and Aasum, 2008).
Methodological limitations may also influence interpretation
of results, however, since absolute rates of flux were not
measured. The studies reporting depressed FA oxidation in the
STZ rat instead reported relative rates of flux, and thus indicated
substrate preference or metabolic flexibility. For instance, when
perfused with both fatty acids and glucose, a lower percentage
of substrate entering the citric acid cycle was derived from fat in
the diabetic heart compared with controls (Chatham and Forder,
1997). Meanwhile the STZ hearts showed a reduced ability to alter
FA oxidation in response to changing concentrations of substrate,
with a 10-fold increase in exogenous palmitate only increasing FA
oxidation by 30% in the diabetic heart, compared with a sevenfold
increase in control rats (Chatham et al., 1999). Since absolute
oxidation rates could not be measured, it is possible that these
studies do not contradict the finding of increased FA oxidation
in the diabetic heart, which was derived from measures of ATP
production from different metabolic substrates (Wang et al.,
2005). Instead, the results may reflect a higher overall metabolic
rate in the diabetic heart, with the relative contribution of fat
being reduced (Chatham and Forder, 1997) and the capacity to
increase FA oxidation in response to increased substrate delivery
limited (Chatham et al., 1999).
The conflicting evidence arising from these studies, highlights
why metabolomic techniques should not be considered in
isolation. FA oxidation, has been investigated by a number of
other, non-metabolomic techniques, including PET (Herrero
et al., 2006; van den Brom et al., 2009), radiolabeled-substrate
oxidation measurements (How et al., 2006), and measurements
of mitochondrial oxidative capacity by respirometry (Kuo et al.,
1983; Vazquez et al., 2015). Such findings are generally in
agreement that FA oxidation is increased in the diabetic heart,
being seen in both animal models of T1DM (STZ mice, How
et al., 2006) and T2DM [both the db/db mouse (How et al., 2006)
and ZDF rat (van den Brom et al., 2009)], as well as women
with T1DM (Herrero et al., 2006). It should be noted, however,
that studies of FA oxidative capacity measured in isolated
mitochondria do show some conflicting results, with a decreased
palmitoyl carnitine-supported OXPHOS capacity reported in
mitochondria from db/db mouse hearts (Kuo et al., 1983), but an
increased capacity for palmitoyl-carnitine supported OXPHOS in
subsarcolemmal mitochondria isolated from the hearts of STZ-
rats (Vazquez et al., 2015). It is worth noting, however, that
respirometry studies of mitochondrial capacity are carried out at
saturating substrate and oxygen concentrations, and thus provide
a robust measurement of respiratory capacity, but may not reflect
that which is occurring in vivo (Lanza and Nair, 2009).
Application of metabolomic techniques to investigate general
changes in the cardiac lipidome have provided further evidence
for alterations to fatty acid oxidation in the diabetic myocardium,
in the form of changes in levels of fatty acid or acylcarnitine
species. In the STZ-induced diabetic rat heart, accumulation of
long-chain (and 3-hydroxylated) acylcarnitine species has been
seen (Su et al., 2005), suggesting a mismatch between delivery of
fatty acid substrate delivery and oxidation rate in this model. This
study also highlights the power of using metabolomic techniques
for investigating changes in lipid metabolism, as although
elevated levels of total acylcarnitine species have been associated
with high rates of FA oxidation (Schooneman et al., 2013), the
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ability to distinguish different chain lengths has demonstrated
that accumulation of long-chain acylcarnitine species specifically
is often associated with β-oxidation dysfunction (Kler et al.,
1991). Moreover, alterations in specific fatty acid species have
also been observed: in the Akita mouse model of T1DM, long-
chain fatty acid species accumulated in the myocardium (Basu
et al., 2009), whilst in the βV59M mouse, relative levels of the
shorter chain myristic acid (C14) and two unsaturated fatty acids
(C16:1 and C18:1) were lower than in non-diabetic controls
(Rohm et al., 2018).
Taken together, these results suggest that glucose metabolism
is suppressed in both T1DM and T2DM. Meanwhile,
metabolomic studies generally support findings that fatty
acid oxidation is elevated in the diabetic heart, although some
inconsistencies do highlight the importance of not considering
metabolomics in isolation.
Other Alterations to Lipid Metabolism
Beyond FA oxidation, alterations to other pathways of lipid
metabolism are evident in DbCM, and may play an important
role in the progression of the pathology. Indeed, one proposed
mechanism for the development of DbCM holds that despite
an initial compensatory increase in FA oxidation capacity,
lipid overload results in the accumulation of harmful lipid
intermediates, a phenomenon known as lipotoxicity (Unger
and Orci, 2000). This, in turn, has been suggested to result in
cardiac mechanical dysfunction. Evidence from animal models to
support such lipid accumulation and altered lipid metabolism in
the diabetic heart is summarized in Table 4.
Lipotoxicity results from ectopic lipid accumulation, and
many studies have demonstrated that the total TAG species
pool is elevated in the diabetic myocardium of human T2DM
cohorts (McGavock et al., 2007; Rijzewijk et al., 2008; Levelt
et al., 2016a) and animal models (Denton and Randle, 1967;
Finck et al., 2003; Coort et al., 2004; O’Donnell et al., 2006; Basu
et al., 2009; Abdesselam et al., 2015). In animals, myocardial TAG
accumulation seems to occur regardless of the model investigated
or type of diabetes. For example, TAG accumulation has been
observed in both mice and rats treated with STZ or alloxan
(Denton and Randle, 1967; Finck et al., 2003; O’Donnell et al.,
2006; Han et al., 2007), Akita mice (Basu et al., 2009), mice
overexpressing peroxisome proliferator-activated receptor-alpha
(PPARα) and treated with STZ (a severe T1DM phenotype)
(Finck et al., 2003), mice fed a diabetogenic high-fat, high-sugar
diet (Abdesselam et al., 2015) and the Zucker fatty rat (Coort
et al., 2004). An increased myocardial TAG pool has also been
associated with obesity in both human and rat studies, correlating
with body mass index (Szczepaniak et al., 2003; Reingold et al.,
2005; Kankaanpää et al., 2006; Utz et al., 2013), and since obesity
is an important risk factor for the development of diabetes (NCD
Risk Factor Collaboration (NCD-RisC), 2016), it is plausible
that TAG accumulation is causative in the development of
DbCM. This hypothesis is supported by a number of 1H-MRS
studies coupled to MRI, which found that increased myocardial
TAG concentration correlates with impaired diastolic function
(Hammer et al., 2008a,b; Rijzewijk et al., 2008) or myocardial
strain (Ng et al., 2010).
In apparent contrast, however, the administration of insulin
therapy to treat T2DM was shown to acutely raise myocardial
TAG concentrations with no apparent functional consequences
(Jankovic et al., 2012). Meanwhile, the development of systemic
insulin resistance in non-diabetic heart failure patients is
associated with decreased rather than increased myocardial TAGs
(Chokshi et al., 2012). Treatment with two anti-glycemic agents
(pioglitazone and metformin) had no effect on myocardial TAG
concentration in men with uncomplicated T2DM compared with
those treated with placebo (van der Meer et al., 2009). Finally, in
a population with metabolic syndrome, though not overt T2DM,
myocardial TAG content was not independently associated with
diastolic dysfunction (Nyman et al., 2013).
It is therefore possible that myocardial steatosis resulting
from TAG accumulation is not the driving force behind the
development of DbCM. Indeed, cellular lipotoxicity is also
associated with accumulation of several other specific lipid
species, including DAGs and ceramides. Several studies, again
in both animal models and human diabetic cohorts, have
demonstrated accumulation of DAGs and ceramides in the
diabetic myocardium both alongside TAG accumulation (Basu
et al., 2009), and in the absence of TAG accumulation (Chokshi
et al., 2012; Wang et al., 2015). DAG accumulation occurs in
Akita mice (Basu et al., 2009) and HFD-fed ob/ob mice (Wang
et al., 2015). DAG accumulation has been shown to correlate
with insulin resistance (Zhang et al., 2011), further implicating
lipotoxic mechanisms in the etiology of DbCM. In studies of right
atrial samples from healthy, obese and obese+T2DM patients,
however, the total content of ceramides were found to be similar
across all three groups, although the levels of individual ceramide
species were not reported (Baranowski et al., 2010).
Increased FA uptake and oxidation in the diabetic heart
may also increase mitochondrial production of reactive oxygen
species (ROS) (Bugger and Abel, 2010), causing oxidative stress
and accelerating the development of DbCM. Lipid peroxidation
has been seen in the STZ rat heart, and this was preventable
with insulin treatment (Jain and Levine, 1995), whilst oxidized
lipids were elevated in the cardiac muscle of the STZ mouse
(Towner et al., 2015). The latter study also utilized a 5,5-dimethyl-
1-pyrroline-N-oxide (DMPO) probe to detect free radicals by
NMR, and found that these increased in the diabetic heart with
specific regional hotspots in the apical and upper left areas of
the left ventricle (Towner et al., 2015). Furthermore, in a study
that reported DAG accumulation in the myocardium of ob/ob
mice fed a HFD, there were increased levels of 8-oxoguanine and
an increased ratio of oxidized/reduced glutathione, indicative of
oxidative stress (Wang et al., 2015), further demonstrating an
association with myocardial lipotoxicity.
Lipidomics: A Tool for Biomarker
Discovery in DbCM
The development and progression of DbCM is associated with
altered levels of specific lipid species in the myocardium, which
has led to the suggestion that lipids might act as plasma-
borne biomarkers for the condition. Shotgun lipidomic studies
have often been used for this purpose (Han et al., 2005,
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TABLE 4 | Changes in lipid metabolites observed to occur in the diabetic myocardium through metabolomic studies in animal models.
Model Lipid metabolites profiled Method References
FA TAG DAG Ch Cer CL PC PE PG PI PS
βV59M mice ↓ GC–MS Rohm et al., 2018
Akita mice ↑ ↑ ↑ ↑ HPLC Basu et al., 2009
MHC-PPAR mice + STZ ↑ ESI-MS Finck et al., 2003
Mice + HFSD ↑ 1H-MRS Abdesselam et al., 2015
ob/ob mice + HFD ↑ LC–MS/MS Wang et al., 2015
Gpat1−/− mice l l l l GC–FID Lewin et al., 2008
Mice + STZ ↑ l QToF MS Han et al., 2007
Mice + STZ ↓ ↓ MS/MS Han et al., 2005
Rat + STZ ↑ NMR O’Donnell et al., 2006
Rat + Alloxan ↑ TLC Denton and Randle, 1967
Zucker Fatty Rat ↑ HPTLC Coort et al., 2004
Rat + STZ ↑ GC Matsui et al., 1997
↓ decreased abundance in diabetic hearts, ↑ increased abundance in diabetic hearts, l specific species increased and others decreased in abundance in
diabetic hearts. HFD, high fat diet; Gpat1, glycerol-3-phosphate acyltransferase 1; MHC-PPAR, myosin heavy chain-peroxisome proliferator-activated receptor gene
cassette; STZ, streptozotocin; HFSD, high-fat high-sucrose diet; FA, fatty acid; TAG, triacylglycerol; DAG, diacylglycerol; Ch, cholesterol; Cer, ceramide; CL, cardiolipin;
PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine; HPLC, high-performance liquid
chromatography; GC, gas chromatography; LC, liquid chromatography; MS, mass spectrometry; FID, flame ionization detector; ESI, electronspray ionization; QToF,
quadrupole time of flight; MRS, magnetic resonance spectroscopy; NMR, nuclear magnetic resonance; TLC, thin-layer chromatography; HPTLC, high-performance
thin-layer chromatography.
2007; Dong et al., 2017, 2018). PC, PE, and SM species
are among the lipid classes identified as potential biomarkers
for DbCM (Dong et al., 2017, 2018), with a number of
species correlating with changes in cardiac function (Dong
et al., 2017). Specifically, the species PC[22:6/18:2], PC[22:/18:1],
PC[20:4/16:1], PE[20:4/18:2], and PE[20:4/16:0] were all found
to be downregulated, and PC[20:2/18:2], PC[18:0/16:0], and
PC[20:4/18:0] upregulated in the myocardium of a high-
sucrose/fat diet +STZ rat model (Dong et al., 2017), with some
perturbations in lipid profiles (e.g., PC[20:4/18:0]) being partially
reversible upon treatment with the phytochemical berberine, the
active ingredient of a traditional Chinese medicine used in the
treatment of diabetes (Dong et al., 2018). Increased levels of
PC and PE species in the sarcoplasmic reticulum membrane
were also shown to occur in the diabetic myocardium, with
decreased levels of species containing arachidonic acid (20:4)
and increased levels of those containing docosahexaenoic acid
(22:6) being detected (Kuwahara et al., 1997). In addition,
changes in several plasma sphingolipid species were found to
correlate with improved fasting insulin in patients with T2DM
(Airhart et al., 2016).
Whilst the findings outlined above demonstrate that induction
of diabetes is associated with changes in lipid metabolism, the
reverse is seen in the Gpat1−/− mouse. This mouse was primarily
developed as a model of altered cardiac FA metabolism, and in
turn it develops some characteristics of diabetes (Lewin et al.,
2008), highlighting a possible causal link between alterations
in lipid metabolism and DbCM. The Gpat1−/− mouse is
characterized by increased cardiac levels of PC, PE, PS, and PI
species with increased arachidonic acid, although this was also
accompanied by a decrease in 16:0-FA containing PC, PE, PS and
PI, and increased PC and PE species containing 18:0 and 18:1
(Lewin et al., 2008).
Other proposed lipid biomarkers include the oxysterol species
7-β-hydroxycholesterol and 7-ketocholesterol (Matsui et al.,
1997) and the relative levels of different cardiolipin species, with
a redistribution of those containing 18:2-FAs to those containing
22:6-FAs detected in STZ-induced diabetic rodent models (Han
et al., 2007), with the latter finding preceding TAG accumulation
in the myocardium. A general decrease in the concentrations
of mitochondrial cardiolipin species was found in the hearts of
STZ mice using shotgun lipidomics (Han et al., 2005). This was
likely bought about by reduced cardiolipin synthesis, since the
metabolic precursor for cardiolipin, phosphatidylglycerol, was
also found to be depleted (Han et al., 2005).
The studies outlined above have mainly examined cardiac
tissue from animal models of DbCM and highlight the possibility
that unique changes in lipid metabolism occur alongside the
pathology. Changes in the plasma lipid profile have been
observed in a lipidomic pilot study, where patients with
T2DM fed a diet rich in medium chain FAs demonstrated
decreased circulating levels of several sphingolipid, ceramide,
and acylcarnitine species implicated in DbCM, whilst patients
fed a diet rich in long chain FAs did not (Airhart et al., 2016).
Whilst further studies are clearly needed, this highlights the
potential of lipidomic approaches for the discovery of plasma-
borne biomarkers for DbCM.
A ROLE FOR KETONE METABOLISM IN
THE DIABETIC MYOCARDIUM?
Oxidation of the ketone bodies, acetone, acetoacetate and
β-hydroxybutyrate, represents a relatively small, but potentially
important source of myocardial ATP. In a 13C-NMR study
of the perfused healthy rat heart, the inclusion of labeled
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glucose, lactate, acetoacetate and long-chain FAs at physiological
concentrations demonstrated that, whilst FA oxidation made
the largest contribution to the cardiac acetyl-CoA pool, 23%
of acetyl-CoA was derived from acetoacetate (Jeffrey et al.,
1995). This suggests that, when ketone bodies are present,
there is some preference for ketone oxidation to meet cardiac
energy requirements in the healthy heart. Two studies utilizing
metabolomic methods, reported that ketone oxidation was
elevated in the (non-diabetic) failing heart of mice and humans
(Aubert et al., 2016; Bedi et al., 2016), highlighting the importance
of ketone metabolism in cardiac pathology.
In diabetic patients, however, ketosis is a serious clinical
complication that requires immediate treatment to prevent
life-threatening acidosis (Chong et al., 2017) and ketones are
therefore usually considered to be detrimental in diabetes.
Perhaps because of this, there are currently few published
studies that have investigated ketone metabolism in the diabetic
heart, although a small number do suggest that cardiac ketone
metabolism is altered in diabetes. Through GC–MS analysis of
arterial and coronary sinus blood, the myocardium of insulin-
dependent diabetics was shown to extract more ketone bodies
that that of healthy control patients (Avogaro et al., 1990).
Cardiac levels of β-hydroxybutyrate were also found to become
elevated over the progression of diabetes in an open-profile
1H-NMR study of the STZ rat (Zhao et al., 2018). Conversely,
administration of empagliflozin, an SGLT2 inhibitor, in a T2DM
patient cohort to reduce hyperglycemia, increased cardiac levels
of β-hydroxybutyrate (Ferrannini et al., 2016). Whilst these
studies indicate alterations in ketone metabolism in DbCM,
whether this represents an adaptation of the heart to diabetes
or a causative factor in the pathogenesis of DbCM needs
further investigation.
AMINO ACID METABOLISM AND
DIABETIC CARDIOMYOPATHY
Recent interest has emerged in BCAA metabolism in the context
of T2DM pathogenesis, with many studies suggesting that
leucine, isoleucine, and valine are involved in the development
of insulin resistance (Bloomgarden, 2018). In the βV59M mouse,
the accumulation of metabolites was investigated by GC–MS and
all three BCAAs were found to be elevated in comparison with
non-diabetic controls (Rohm et al., 2018). Meanwhile in the STZ
rat heart, 1H-NMR spectroscopy showed that valine, leucine,
and isoleucine all became elevated during the progression of
diabetes (Zhao et al., 2018). Furthermore, BCAAs were found
to be released by the T1DM human heart, but not by healthy
hearts (Avogaro et al., 1990), providing further evidence for
elevation of BCAA production or depressed catabolism in the
diabetic myocardium.
It is noteworthy, however, that other aspects of amino acid
metabolism may be altered in the diabetic heart. Metabolic
profiling of a diabetic rat model which expresses human
pancreatic amylin (HIP-model) highlighted several amino acid
species (including phenylalanine, tyrosine, glycine, serine, and
lysine) the concentrations of which were altered in the diabetic
hearts (Ilaiwy et al., 2016). Although the HIP-model is a very
specific diabetic phenotype, where diabetes is induced over
time through increased proteotoxicity in pancreatic β-cells, the
authors found that the metabolome of their model demonstrated
a similar fall in glycine levels and increase in lysine compared
with strain-matched T2DM rats in a untargeted metabolomic
study (Ilaiwy et al., 2016), indicating that altered amino




Metabolomic techniques are proving to be valuable in helping
to unravel the metabolic disturbances of DbCM. Open profiling
methods may lead to the identification of putative biomarkers
in animal models of DbCM, whilst targeted approaches have
highlighted alterations in lipid, ketone, and amino acid pathways.
Despite this, unanswered questions remain regarding
metabolism in the diabetic heart, which could be addressed
in future studies using metabolomic techniques. Firstly, the
time course of metabolic derailment in DbCM is unclear.
Open-profiling experiments, coupled with longitudinal study
designs, could be useful in elucidating this timeline. Lack of a
conclusive time course also means that the causal relationship
between changes in metabolism and cardiac dysfunction has not
been shown; although metabolic derailment is often considered
to be causal in the progression of the diabetic myocardium
toward overt failure, changes in metabolism may in turn
arise as a consequence of mechanical dysfunction. However,
if aspects of metabolic remodeling are indeed causal in the
development of DbCM, then mechanistic detail needs to be
elucidated. Here, more targeted metabolomic techniques will
be useful. By monitoring changes in key metabolic pathways,
the stage at which alterations to metabolism occur may become
apparent. This strategy might highlight enzymes or subcellular
compartments (e.g., mitochondria versus cytoplasm) affected
by DbCM to suggest mechanisms underpinning dysfunction.
Meanwhile, the results of studies demonstrating alterations in
cardiac metabolism in diabetes need to be placed in context,
and here complementary techniques are useful in indicating
how changes in metabolite concentrations or flux correspond to
alterations in, e.g., mitochondrial respiratory capacity (Ashmore
et al., 2014; Wang et al., 2015) or cardiac function in vivo (Le
Page et al., 2015) or ex vivo (Dodd et al., 2018). Further work is
needed to determine whether elevated myocardial ketone bodies
are beneficial or detrimental to the diabetic heart. Finally, it is
important to remember that diabetes is a systemic condition, and
therefore changes in metabolism in organs other than the heart
may also play a role in the progression of dysfunction in the
diabetic heart. Accordingly, the interactions between the heart
and other organs require further investigation.
Some inconsistent findings surrounding metabolism in the
diabetic myocardium may have arisen through differences in
animal models used, or the type of diabetes studied. Indeed,
whilst metabolic derangements are apparent in the hearts
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of rodent models of both T1DM and T2DM, the clinical
presentation of DbCM in T1DM patients has been considered
more controversial than in T2DM cohorts (Hölscher et al., 2016).
Metabolomic studies have shown that many similarities exist
between T1DM and T2DM hearts, with depressed glucose and
pyruvate oxidation and accumulation of TAGs and DAGs seen
regardless of the model studied (Figure 1). Discrepancies have
been reported between studies of cardiac energetics in different
T2DM models, and this might be explained by the severity of
the model or the timepoint studied, since DbCM is a progressive
condition. Disagreement on the pattern of changes in fatty acid
oxidation between models of T1DM and T2DM, may reflect the
nature of the T1DM model. Whilst STZ treatment is the most
commonly used method of generating T1DM, it is known to have
effects beyond the ablation of pancreatic β-cells, for example,
causing cytotoxicity in liver and kidney owing to the high
density of GLUT2 in these organs (Lenzen, 2008). GLUT2 is not
expressed in heart, and STZ is therefore unlikely to accumulate
in cardiac tissue (Schnedl et al., 1994), but may nevertheless
exert effects on cardiac metabolism and mitochondrial function
through mechanisms beyond insulin depletion. Future studies
that investigate fatty acid oxidation via metabolomic methods
in other models of T1DM, such as the NOD mouse or the
surgical rat pancreatectomy model (Thisted et al., 2018) would
be therefore informative.
A significant disadvantage of metabolomic techniques is
that findings typically reflect metabolite levels at a single time
point, whereas in vivo metabolite concentrations are rarely
static (although they may be at steady state) and metabolites
constantly flux through a variety of metabolic pathways. Some
techniques have tried to overcome this limitation including
hyperpolarized-13C MRS studies measuring, for example, PDH
flux (Schroeder et al., 2008; Le Page et al., 2015; Rohm et al., 2018),
and stable isotope tracing experiments, designed to observe
which metabolites accumulate following administration of a
specific labeled substrate (e.g., Chatham and Forder, 1993, 1997;
Chatham et al., 1999; Chatham and Seymour, 2002; Wang
et al., 2005; O’Donnell et al., 2006). Nevertheless, metabolomic
techniques should be combined with other techniques to
provide a comprehensive overview of metabolism in the
diabetic heart. This is especially evident when considering FA
oxidation in the diabetic heart; metabolomic approaches suggest
conflicting evidence regarding whether FA oxidation is elevated
in DbCM, whilst non-metabolomic methods are more conclusive
(Figure 1). It is therefore imperative that metabolomics are not
considered in isolation.
One such technique, that has been utilized widely in human
studies (e.g., Monti et al., 2004; Peterson et al., 2004; Herrero
et al., 2006; Bucci et al., 2012), and some animal models (e.g.,
Welch et al., 2006; Shoghi et al., 2008; van den Brom et al., 2009),
is PET. Whilst often used to aid disease diagnosis, especially
in the diagnosis of cancer metastasis, PET can be used to
investigate alterations to metabolism. Substrates, labeled with a
radioactive tracer such as 18F, 11C, 13N and 15O, are taken up by
metabolically-active tissues including the heart, and radioactive
decay of the tracer can then be measured, indicating uptake
FIGURE 1 | Summary of evidence from animal models concerning cardiac metabolic alterations in type-1 and type-2 diabetes. Subscripts denote the models in
which investigations have been carried out. T1DM, type-1 diabetes; T2DM, type-2 diabetes; DbCM, diabetic cardiomyopathy; FAO, fatty acid oxidation; TAG,
triacylglycerol; DAG, diacylglycerol; STZ(R), streptozotocin-rat model; STZ(M), streptozotocin-mouse model; MHC-PPAR, myosin heavy chain-peroxisome
proliferator-activated receptor gene cassette; HFD, high fat diet; ZDF, Zucker diabetic fatty; HFSD, high-fat high-sucrose diet.
Frontiers in Physiology | www.frontiersin.org 11 May 2019 | Volume 10 | Article 639
fphys-10-00639 May 31, 2019 Time: 10:4 # 12
Sowton et al. Diabetic Cardiomyopathy – Insights From Metabolomics
and flux of the tracer in tissues of interest. Although expensive,
owing to the cost of producing the tracers and instrumentation,
metabolic and cardiovascular parameters such as myocardial
blood flow, myocardial oxygen consumption, and substrate
specific uptake, utilization, and oxidation (Peterson et al., 2004)
can be measured in vivo, making PET a useful, non-invasive
tool for investigating metabolism in DbCM. Combining PET
with metabolomics (e.g., Rijzewijk et al., 2009; Bucci et al., 2012;
Abdurrachim et al., 2017) therefore has the potential to reveal
in vivo changes in flux of targeted metabolites and to identify
novel alterations in metabolic pathways in an unbiased manner.
Finally, novel applications of metabolomic techniques may
also help to elucidate metabolic changes in the diabetic
myocardium. MSI is an application of MS that enables the
distribution of tissue metabolites to be analyzed in situ (Hall
et al., 2017). Unlike traditional MS, MSI does not damage the
integrity of the tissue of interest, as metabolites are directly
ionized from the surface of the tissue, allowing a comparison
to be drawn between metabolite distribution and underlying
tissue histology (Addie et al., 2015). This technique has been
used, for example, to demonstrate changes in the hepatic
zonation of lipids in non-alcoholic fatty liver disease (Hall
et al., 2017) and alterations to phospholipid distribution across
an infarction in the rat heart (Menger et al., 2012). It could
therefore be beneficial to apply MSI to the diabetic myocardium
to assess spatial changes across the heart over the progression
of DbCM and relate them to contractile dysfunction or local
energetic profiles in order to fully elucidate the mechanism of
metabolic pathology.
CONCLUSION
Metabolomic studies have helped to elucidate metabolic
derangements that occur in the diabetic heart. Glycolysis and
glucose oxidation are depressed in DbCM and it is highly likely
that this is accompanied by energetic impairment. Open-profiling
lipidomic studies have demonstrated that that there are specific
classes of lipid, and individual species within these classes, that
are distinctly altered in the diabetic myocardium and some of
these species might serve as biomarkers for DbCM, particularly
if they relate to alterations in circulating lipid species. There
are, however, questions remaining concerning the physiological
significance of lipid remodeling and the mechanistic role this
might play in the pathology. For instance, whilst it has been
postulated that lipotoxicity may be a driving force behind
functional impairment, whether changes in individual lipid
species are causal in the development and/or progression
of DbCM, or a simply consequence of the condition needs
further investigation.
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